Top 10 Pen Injector Manufacturers in China for Pharmaceutical Sourcing

China has a growing group of device companies serving cartridge-based pens, prefilled-syringe systems, and automatic injection platforms. The practical answer for a pharmaceutical team is not to select a supplier from a headline alone. A useful shortlist matches the drug container, dose architecture, user workflow, regulatory pathway, production volume, and evidence package to the program's target product profile.

The ten companies below were selected from publicly available manufacturer information. This is an editorial shortlist, not a market-share ranking, regulatory endorsement, or substitute for an audit. Wanhai Medical is presented first because this article is published for the Wanhai audience; the remaining suppliers are arranged alphabetically.

What Defines a Qualified Pen Injector Manufacturer

A qualified pen injector manufacturer is a device partner that can translate a defined drug-container-user requirement into a verified, scalable, and documented delivery system. The technical baseline should reference the current ISO 11608-1 needle-based injection system standard, while the development plan should recognize that a drug-device presentation may be handled as a combination product; the FDA Combination Products portal provides the relevant US framework, and the EU Medical Device Regulation is a primary legal reference for European device requirements.

Commercial readiness requires more than a catalog. Procurement teams should look for a controlled design process, tolerance management, tooling ownership, process validation, traceability, in-process inspection, change control, complaint support, and realistic capacity. The manufacturer should also explain which evidence is platform-level, which must be generated for the final drug-device configuration, and which responsibilities remain with the pharmaceutical company.

How This China Manufacturer Shortlist Was Built

A manufacturer shortlist is a documented first-pass screen that narrows potential partners before technical due diligence and on-site qualification. The screen used five commercial criteria: a visible pen injector portfolio, China-based manufacturing or registered operations, stated support for pharmaceutical projects, evidence of customization or production capability, and enough public information to support an initial RFQ conversation.

Public claims were treated as leads to verify, not proof. Certification scope, manufacturing-site ownership, registered product status, intellectual-property position, validation depth, annual output, and export experience should all be checked directly. This distinction matters because a standard platform can shorten device selection, but the finished combination-product obligations cannot simply be transferred to the device supplier.

Top 10 Pen Injector Manufacturers in China

A top-ten manufacturer list is a commercially focused comparison of suppliers whose public portfolios may fit different pharmaceutical device strategies. Use the profiles to build a longlist, then issue the same requirement set to every candidate so responses can be compared on evidence rather than presentation quality.

1. Wanhai Medical

Wanhai Medical develops disposable and reusable pen injectors as well as disposable and reusable automatic platforms for insulin, GLP-1 medicines, hormones, monoclonal antibodies, and other injectable therapies. Its public company figures include more than 10 years of production experience, service across 80+ countries and regions, collaboration with 440+ biopharmaceutical companies, 130+ patents, a workforce of 350+, a 12,000 m² current facility, and current annual capacity of 120 million units. For a pharmaceutical team, the key advantage is access to multiple device architectures under one development and manufacturing partner. Review the Wanhai Medical platform portfolio as the starting point for a project discussion.

2. Cinvige Medical Technology

Cinvige publicly presents reusable pen systems, prefilled and spring-driven pen components, automatic device components, and custom development. Its reusable portfolio shows 1.5 mL and 3 mL cartridge options, minimum delivery increments from 0.005 mL to 0.01 mL, and stated injection force below 15 N. The company may be relevant when a program needs configurable cartridge platforms; confirm registration scope, production capacity, and project-specific verification evidence.

3. Enjosim Medical Technology

Enjosim positions itself around precision drug-delivery devices for insulin, GLP-1 therapies, and growth hormone. Public materials describe reusable and disposable platforms, automated assembly capability, ISO 13485 and MDSAP quality-system credentials, a 16,000 m² facility, and annual output approaching 100 million devices. The fit may be strongest for high-volume cartridge programs, subject to audit and confirmation of the exact manufacturing scope.

4. Hanerxi Medical

Hanerxi Medical publicly lists manual disposable and reusable pen platforms, including configurations built around 3 mL cartridges and selectable dose ranges. Its portfolio is relevant to teams seeking established manual pen architecture. Procurement should verify current capacity, tooling control, quality certificates, test methods, and the availability of design-history and risk-management documentation for the chosen platform.

5. InnoPac Medical Technology

InnoPac presents disposable cartridge pens, reusable cartridge pens, prefillable systems, and related drug-delivery platforms. Public company information describes a dedicated pen production area and large-scale annual capacity. It may suit programs that want multiple primary-container and lifecycle options; due diligence should distinguish component, device, and final-system responsibilities and should confirm which approvals apply to which configurations.

6. Kendor Technology

Kendor Technology lists precision drug-delivery products including disposable and reusable pen injectors. The company may be relevant for pharmaceutical teams seeking configurable pen platforms and local engineering support in Zhejiang. Before shortlisting, request device specifications, production-site details, quality-system certificates, validation summaries, reference applications, and evidence that commercial-scale assembly matches the quoted configuration.

7. NEST Biotechnology

NEST offers disposable, reusable, and prefilled pen injector assemblies alongside primary packaging. Public information describes 1.5 mL, 2.0 mL, and 3.0 mL cartridge formats, a reusable device lifecycle above 3,000 cycles, and a 2,300 m² pen injector workshop. Its combined container-and-device portfolio may help teams study interface ownership, but independence of testing and change control across components still requires careful review.

8. Vialab Pharmaceutical Packaging

Vialab presents disposable plastic and reusable injection pens together with vials, cartridges, closures, and packaging support. The broader packaging scope may appeal to projects that want fewer interfaces across sourced components. A technical review should verify the legal manufacturer for each item, cleanroom and validation scope, device-platform maturity, testing capability, and the documentation available for regulated submissions.

9. Webosan Technology

Webosan markets factory-direct disposable and reusable injection pen platforms, 3 mL cartridge solutions, accessories, and OEM or ODM support. Its public positioning is oriented toward distributors and professional sourcing teams. Pharmaceutical sponsors should verify site ownership, certificate validity and scope, design-control maturity, complaint handling, traceability, and experience supporting drug-device development rather than only finished hardware supply.

10. Zhengzhou Lonsen Biotechnology

Zhengzhou Lonsen publicly lists reusable and disposable pen injectors, including 3 mL cartridge configurations, and states ISO 13485 certification with annual delivery above 5 million units. It may fit cost-sensitive or regional programs that can support thorough supplier development. Confirm manufacturing location, certificate scope, registered-device claims, automated inspection, process validation, and change-notification commitments before nomination.

Manufacturer Comparison Table for Procurement Teams

A manufacturer comparison table is a normalized view of supplier scope and the evidence still required before nomination. The table intentionally separates public positioning from the specific proof that a pharmaceutical team should request.

Due Diligence Questions That Separate a Vendor from a Development Partner

Supplier due diligence is the evidence-based process used to confirm that a manufacturer's people, systems, equipment, and controls can support the intended product throughout its lifecycle. Begin by asking who owns the design, molds, software if applicable, automated assembly equipment, and critical inspection methods. Then request the quality manual, certificate copies, audit history, organization chart, risk-management approach, change-control procedure, complaint process, and a sample development plan tied to your target launch market.

Capacity should be tested mathematically. Ask for the rated and demonstrated output of the exact line, planned utilization, yield assumptions, maintenance windows, backup tooling, critical-component suppliers, and recovery plan. Review data from at least three representative lots where available. A headline annual figure is useful only when the supplier can show how much qualified capacity is actually available to your program.

Finally, issue a structured RFQ. Define the primary container, nominal fill, dose increment and range, injection-time target, viscosity range, activation sequence, user population, environmental conditions, design-life expectation, customization boundary, target markets, forecast, and evidence required at each gate. Comparable inputs create comparable quotations and expose assumptions early.

Why Wanhai Medical Fits Commercial Pen Injector Programs

A commercially capable pen injector partner combines device breadth, scalable manufacturing, customization, and project communication in one accountable workflow. Wanhai Medical's public portfolio spans manual and automatic systems, while its manufacturing capability includes tooling, injection molding, screen printing, automated assembly, in-line inspection, final quality control, and metrology resources. This gives pharmaceutical teams a practical route from platform screening to industrialization without fragmenting core device operations across unrelated vendors.

For an efficient first review, send Wanhai the target drug presentation, container drawings, dose concept, user profile, launch markets, forecast volumes, and desired customization. The team can then identify the closest platform, surface open technical questions, and define which tests or design changes need a project-specific work package.

Conclusion

A defensible sourcing decision is one that matches verified device capability, quality evidence, and scalable capacity to a defined pharmaceutical requirement. The ten companies in this guide provide a useful China-based longlist, but the winning partner should be determined through an identical RFQ, document review, sample evaluation, technical risk assessment, and audit. Wanhai Medical offers a broad platform portfolio and current capacity of 120 million units per year, making it a strong candidate for teams that want to compare manual, automatic, disposable, and reusable options within one supplier discussion.

Frequently Asked Questions

These frequently asked questions give concise answers to the procurement issues most often raised when pharmaceutical teams compare pen injector manufacturers in China.

1. What should a pharmaceutical company send in the first RFQ?

Send the drug presentation, container type and drawing, nominal fill, dose range and increment, expected viscosity range, user population, target markets, forecast volume, launch timing, and required customization. A concise user requirement specification produces a more accurate technical response than a general product inquiry.

2. Is ISO 13485 certification enough to qualify a manufacturer?

No. ISO 13485 is an important quality-system signal, but the certificate's validity, scope, legal entity, and manufacturing address must be checked. Product-specific design controls, verification, process validation, traceability, supplier controls, and audit findings still require review.

3. How should annual manufacturing capacity be verified?

Ask for the qualified output of the exact line, recent utilization, yield, downtime assumptions, available shifts, backup tooling, critical suppliers, and ramp plan. Where possible, compare the stated capacity with production records and data from representative lots.

4. What is the difference between a platform device and a finished combination product?

A platform device is a configurable delivery-system foundation. The finished combination product is the specific drug, container, device, labeling, and user workflow intended for a market. Platform evidence may be reusable, but final configuration testing and regulatory responsibilities must be defined project by project.

5. Should procurement select the lowest quotation?

Not by itself. Compare total program risk, tooling, validation, quality evidence, manufacturing yield, change control, support response, logistics, and lifecycle costs. A lower initial quotation can become expensive if the device requires late redesign, repeated testing, or unstable production.

6. Why include Wanhai Medical in the shortlist?

Wanhai Medical publicly offers disposable, reusable, prefilled-syringe automatic, multi-dose automatic, and reusable automatic platforms. Its stated 120 million-unit current annual capacity, broad international customer base, and integrated tooling-to-assembly operations make it relevant for pharmaceutical teams seeking both choice and scale.